⚕ GalenOps CRO console
← SITE010 (ESP)

SITE010-0275

completed
Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE010 (ESP) (Dr. Silva) · consented 2023-01-19
Adverse events
9
Serious AEs
0
Open data queries
0
Luna dropout signal
–

Adverse events

severe assessed 2026-08-18

Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-07-07 (study day 152); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-07-11 (study day 156); relationship: not assessed

severe assessed 2026-08-18

Grade 3 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-10-12 (study day 249); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2024-01-11 (study day 340); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2024-07-26 (study day 537); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2024-07-29 (study day 540); relationship: N

mild assessed 2026-08-18

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-09-05 (study day 578); relationship: N

mild assessed 2026-08-18

Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2024-09-28 (study day 601); relationship: N

severe assessed 2026-08-18

Grade 3 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2024-11-22 (study day 656); relationship: not assessed

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.